Please assess the completion status of the following clinical trial:

Trial Title: GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant must have been male or female, aged between 2 and 18 years (inclusive).~* Participant must have had a documented history of Dravet syndrome that was not completely controlled by current antiepileptic drugs.~* Participant must have been taking 1 or more antiepileptic drugs at a dose that had been stable for at least 4 weeks.~* All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation) must have been stable for 4 weeks prior to screening and participant was willing to maintain a stable regimen throughout the study.~Key Exclusion Criteria:~* Participant had clinically significant unstable medical conditions other than epilepsy.~* Participant had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to screening or randomization, other than epilepsy.~* Participant was currently using or had in the past used recreational cannabis, medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to study entry and was unwilling to abstain for the duration for the study.~* Participant had any known or suspected hypersensitivity to cannabinoids or any of the excipients of the investigational medicinal products.~* There were plans for the participant to travel outside their country of residence during the study.~* Any history of suicidal behavior or any suicidal ideation of type four or five on the Columbia-Suicide Severity Rating Scale (Children's) at screening.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 10 mg/kg/day GWP42003-P (Type: EXPERIMENTAL): GWP42003-P oral solution (100 mg/milliliter \[mL\] cannabidiol in sesame oil with anhydrous ethanol with added sweetener \[sucralose\] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
- 20 mg/kg/day GWP42003-P (Type: EXPERIMENTAL): GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener \[sucralose\] and strawberry flavoring). The 20 mg/kg/day dose was recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206).
- Placebo Control (Type: PLACEBO_COMPARATOR): Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.

Based on this trial design, predict the completion outcome and termination type (if applicable).